Potential pathologic markers for prostate chemoprevention studies.
The field of exploring potential biomarkers for prostate cancer prevention continues to expand rapidly. In addition to a limited scope of histologic alterations, mainly PIN, a growing array of promising technologies (eg, computer-assisted analysis), and molecules involved in cell-cycle regulations, angiogenesis, and structural and numerical chromosomal alterations are potential candidates for surrogate endpoint biomarkers for prevention trials. Before any these potential candidates are adopted, however, the technical, interpretational, and validation requirements must be satisfied. More important, it is crucial to demonstrate that modulation of the frequency of the biomarker decreases the rate of cancer development.
Sakr
Wael A
WA
Department of Pathology, School of Medicine, Wayne State University, 540 East Canfield, Detroit, MI 48201, USA. waskr@med.wayne.edu
Lucia
M Scott
MS
D000230:Adenocarcinoma / Q000401:mortality / Q000473:pathology / Q000517:prevention & control; D000368:Aged; D014408:Biomarkers, Tumor / Q000032:analysis*; D018890:Chemoprevention / Q000379:methods*; D019587:Dietary Supplements; D006801:Humans; D008297:Male; D008875:Middle Aged; D009389:Neovascularization, Pathologic / Q000175:diagnosis; D017430:Prostate-Specific Antigen / Q000032:analysis; D019048:Prostatic Intraepithelial Neoplasia / Q000401:mortality / Q000473:pathology / Q000517:prevention & control; D011471:Prostatic Neoplasms / Q000401:mortality / Q000473:pathology* / Q000517:prevention & control*; D018570:Risk Assessment; D012643:Selenium / Q000008:administration & dosage; D012680:Sensitivity and Specificity; D016019:Survival Analysis; D014810:Vitamin E / Q000008:administration & dosage
D014408:Biomarkers, Tumor; D014810:Vitamin E; D017430:Prostate-Specific Antigen; D012643:Selenium